SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has ...

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down the long-term thesis. You’re reading a free article with opinions that may differ from The ...

ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed ...

April 23 (Reuters) - Resmed (RMD.N), opens new tab beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep ...

ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple ...

ResMed (NYSE:RMD) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-23. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. With cloud ...

13. NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a ...

(RTTNews) - Resmed (RMD), Thursday announced it has acquired VirtuOx, an independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. "This is about creating a ...